Haemophilus meningitis

Summary

Haemophilus meningitis (MONDO:0000889) is a disease. A subtype of bacterial meningitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	haemophilus meningitis
Mondo ID	MONDO:0000889
EFO	EFO:1000955
MeSH	D008583
DOID	DOID:0080179
SNOMED CT	192643004, 5900006
UMLS	C0025292
MedGen	7535
GARD	0022838
MedDRA	10018953
Is cancer (heuristic)	no

Also known as: Haemophilus influenzae bacterial meningitis · Haemophilus influenzae caused bacterial meningitis

Disease family

This is a subtype of bacterial meningitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › encephalomyelitis › meningitis › infectious meningitis › bacterial meningitis › haemophilus meningitis

Related subtypes (7): streptococcal meningitis, anaerobic meningitis, meningeal tuberculosis, Escherichia coli meningitis, Listeria meningitis, meningococcal meningitis, bacterial meningitis caused by gram-negative bacteria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Hepatitis B Virus Hbsag Surface Protein Antigen	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.